months ago, the FDA approved the first combined inhibitor therapy pill for melanoma: Dabrafenib and trametinib,
designed to block certain BRAF enzyme pathway genetic mutations. These mutations occur in approximately ... circumvented.
So far after one year of clinical trial treatment on the combined pill, Dabrafenib and Trametinib, 41% of melanoma
patients were progress-free compared with only ... monotherapy Dabrafenib arm. The inhibitor combination
also reduced the resistant emergence of secondary cutaneous squamous cell carcinoma, down to 2% from 19% in the
Dabrafenib monotherapy group